Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Essilor - News Release: Publication of the 2018 Interim Financial Report

Posted on: 26 Jul 18

Publication of the 2018 Interim Financial Report

PDF version of the news release

Charenton-le-Pont, France (July 26, 2018 - 6:30 am) - The Essilor International (Compagnie Générale d'Optique) 2018 Interim Financial Report is being published today.

The Board of Directors of Essilor met on July 25, 2018 to approve the financial statements for the six months ended June 30, 2018.

The report comprises the interim consolidated financial statements, the interim management report, the statement by the person responsible for the interim financial report and the auditors' review report on the interim consolidated financial statements.

It can be downloaded from the Company's website,, in the "Investors / Publications and Downloads" section, or by clicking on:

About Essilor
Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, EyezenTM, Xperio®, Foster Grant®, BolonTM and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals.
Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit
The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices. 
Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.


Investor Relations and Financial Communications
Phone: +33 (0)1 49 77 42 16



Last updated on: 26/07/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.